Novo Nordisk and Ozempic: The GLP-1 Portfolio Explained

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic is often discussed as if it stands alone, but it is one entry in Novo Nordisk's larger GLP-1 lineup — and understanding that lineup clarifies what Ozempic is and isn't. This guide maps the portfolio, the FDA-approved indications behind each product, and how the competitive picture actually looks. Start at our Education Hub for the broader library.

Where Ozempic sits in the portfolio

Novo Nordisk markets Ozempic (semaglutide, FDA-approved for type 2 diabetes in 2017), Wegovy (semaglutide 2.4 mg, FDA-approved for chronic weight management in 2021), Rybelsus (oral semaglutide, FDA-approved for type 2 diabetes in 2019), Victoza (liraglutide, FDA-approved for type 2 diabetes in 2010 with a 2017 cardiovascular indication), and Saxenda (liraglutide 3 mg, FDA-approved for chronic weight management in 2014). The pipeline includes emerging obesity agents such as CagriSema, a cagrilintide-plus-semaglutide combination.

One molecule, multiple products

Ozempic, Wegovy, and Rybelsus all center on semaglutide but carry distinct FDA-approved indications and formats. That is why the same active ingredient shows up under different brand names — each product is approved for a specific use, not interchangeable across indications.

How Novo Nordisk compares to Eli Lilly

The two companies dominate the GLP-1 landscape with different molecular strategies. Novo Nordisk focuses on GLP-1-selective compounds (semaglutide, liraglutide), while Eli Lilly markets the only FDA-approved GIP/GLP-1 dual agonist (tirzepatide) and a GLP-1-selective option (dulaglutide). Head-to-head trials — SURPASS-2 (tirzepatide vs semaglutide 1 mg in type 2 diabetes) and SUSTAIN 7 (semaglutide vs dulaglutide) — inform the picture, though direct weight-management head-to-head data is limited.

Cost positioning

Manufacturer list prices are broadly similar across branded products — typically $800–$1,600 per month at U.S. list as of April 2026. Savings-card programs differ by product, and patient-assistance programs exist at both companies for eligible uninsured or underinsured patients. Compounded alternatives through 503A pharmacies are priced separately.

Shared safety profile

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists across both manufacturers carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal, and rare serious events include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

The genetics upstream of every product

Regardless of manufacturer, the same pathway-level genetics sit underneath. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, and before any protocol the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology. It does not predict response to any manufacturer's products.

Why brand names outpace understanding

Ozempic became a household word faster than most people learned what it actually is, which is part of why so much confusion surrounds it. A single molecule — semaglutide — appears under multiple brand names with different approvals, and casual conversation tends to blur those lines. Slowing down to see the portfolio as a whole is the antidote to that blur.

Understanding the structure also clarifies the choices ahead of any provider conversation. Knowing that Ozempic, Wegovy, and Rybelsus share an active ingredient but differ in indication and format helps you ask sharper questions and interpret coverage rules more accurately. The brand names are marketing; the molecules, indications, and safety profile are the substance — and it is the substance that should anchor any decision made with a healthcare provider.

For anyone comparing options, that substance-over-branding mindset is the most useful tool available. It lets you cut through overlapping names and marketing to focus on indication, evidence, safety, and — underneath all of it — the pathway-level biology that a genetic profile can help illuminate before any protocol conversation with a provider begins.

None of this is meant to steer you toward or away from any product. It is meant to make you a more capable participant in your own care — someone who can read a portfolio, weigh evidence and safety honestly, and bring genuine questions to a provider rather than absorbing whichever brand name happens to be loudest in the moment.

Frequently Asked Questions

What GLP-1 products does Novo Nordisk make?

Novo Nordisk markets Ozempic (semaglutide for type 2 diabetes), Wegovy (semaglutide 2.4 mg for chronic weight management), Rybelsus (oral semaglutide for type 2 diabetes), Victoza (liraglutide for type 2 diabetes), and Saxenda (liraglutide 3 mg for chronic weight management). Each product has a distinct FDA-approved indication.

Which company makes the most effective GLP-1?

Effectiveness is trial-specific and population-specific. SURPASS-2 (tirzepatide vs semaglutide 1 mg in type 2 diabetes) and SUSTAIN 7 (semaglutide vs dulaglutide 1.5 mg) inform the picture, but direct weight-management head-to-head data is limited. Individual response varies widely — discuss it with a provider who can weigh personal factors.

How do costs compare between the two companies?

Manufacturer list prices are broadly similar — typically $800–$1,600 per month at U.S. list as of April 2026. Savings programs, insurance coverage, and out-of-pocket cost vary more by product, plan, and indication than by manufacturer. Verify current terms at the time of fill.

How does the genetic test relate to these products?

It does not predict response to any specific manufacturer's products. The Precision Peptide Genetic Test analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across both Novo Nordisk and Eli Lilly compounds.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.